{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-019779","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.850514+00:00","generated_at":"2026-05-25T13:50:33.265445+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adial Pharma FY2024 net loss $13.2M, cash $3.8M; FDA confirms AD04 505(b)(2) path","bullets":["Net loss $13.2M in FY2024 versus $5.1M in FY2023; widened primarily on $4.5M non-cash inducement charge.","Cash and equivalents $3.8M at year-end; expects to fund operations into H2 2025.","R&D spend rose $1.9M (+155%) driven by PK study and CMC manufacturing for AD04 Phase 3.","FDA confirmed 505(b)(2) bridging strategy; Phase 3 trial to begin in 2025.","Appointed Vinay Shah as CFO in November 2024; secured three new U.S. patents for AD04 genetic diagnostics."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-019779","json":"https://secwatch.observer/filing/0001213900-25-019779.json","markdown":"https://secwatch.observer/filing/0001213900-25-019779.md","text":"https://secwatch.observer/filing/0001213900-25-019779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025019779/0001213900-25-019779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025019779/ea0232881-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T13:50:33.265445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}